Clear cell sarcoma is a rare cancer that starts in tendons or deep soft tissues, often in the arms or legs. People with clear cell sarcoma may notice a slow-growing, firm lump that can be tender or painless. It tends to affect teens and young adults but can occur at any age, and it can spread to lymph nodes or lungs over time. Treatment usually involves surgery, and many also receive radiation or chemotherapy, with regular scans to watch for return or spread. The outlook for clear cell sarcoma varies by tumor size, location, and stage, and close follow-up is important.
Overview
Clear cell sarcomaSymptoms
Clear cell sarcoma often appears as a firm, slowly growing lump on a foot, ankle, or hand, painless at first. Early symptoms of Clear cell sarcoma include swelling, tenderness, or limited movement; later, pain, numbness, or enlarged nearby lymph nodes.
Outlook and prognosis
Clear cell sarcoma tends to grow slowly but can spread to nearby lymph nodes and the lungs, sometimes years after diagnosis. Outcomes are better with complete surgical removal and careful follow-up. Regular imaging and prompt treatment of any recurrence improve long‑term control.
Causes and risk factors
Clear cell sarcoma is driven by an acquired gene fusion in the tumor, usually involving EWSR1, and isn’t inherited. Environmental or lifestyle risks aren’t established; most cases arise without a known trigger. It tends to affect adolescents and young adults.
Genetic influences
Genetics is central in clear cell sarcoma. Most tumors carry a specific gene fusion—often EWSR1-ATF1, sometimes EWSR1-CREB1—which drives growth and helps confirm diagnosis. These changes are usually not inherited; family risk is generally low.
Diagnosis
Clear cell sarcoma is diagnosed with imaging to define the mass (usually MRI or CT) and a biopsy. Pathologists confirm the diagnosis under the microscope and with molecular tests that detect the EWSR1 gene fusion; scans then stage disease.
Treatment and drugs
Treatment for clear cell sarcoma is tailored by a sarcoma team and often includes surgery to remove the tumor with a clear margin. Depending on size, location, or spread, doctors may add radiation or chemotherapy, and newer targeted or immunotherapy options. Regular imaging and follow-up help guide any further treatment.
Symptoms
A clear cell sarcoma often shows up as a firm lump in an arm or leg, commonly the foot or ankle, that doesn’t go away. Symptoms vary from person to person and can change over time. Early symptoms of clear cell sarcoma are often subtle—a small, painless bump that slowly grows or starts to bother you with activity. Over time, the area may ache, feel tight, or affect how clothing or shoes fit.
A firm lump under the skin near a tendon or joint is common. It usually doesn’t hurt at first and may feel fixed in place. With clear cell sarcoma, this lump tends to persist rather than come and go.
The mass often enlarges slowly over months. The gradual change makes it easy to dismiss, but steady growth is a reason to get it checked. Even small increases in size can matter.
As the mass presses on nearby tissues, you may feel aching, tenderness, or sharp pain. Activity or wearing tight shoes may make it worse. Some people with clear cell sarcoma notice pain at night or at rest as it grows.
The area can look puffy or feel full. On the foot or ankle, shoes may feel tighter or rub in a new spot. Swelling doesn’t always match the size of the lump.
How people usually first notice Clear cell sarcoma?
Many people first notice clear cell sarcoma as a small, firm lump on or near a tendon or aponeurosis, often in the foot, ankle, or hand, that slowly grows over months and may start to ache or feel tender with activity. Because it’s deep in soft tissue and can look like a benign sports injury or ganglion cyst, it’s often found when a lump doesn’t go away, gets larger, or begins to limit movement. Doctors usually suspect it when imaging shows a well-defined deep soft‑tissue mass and a biopsy confirms the diagnosis; these are the first signs of clear cell sarcoma that lead to further care.
Types of Clear cell sarcoma
Clear cell sarcoma is a rare cancer that most often starts in tendons and soft tissues, and it tends to act differently depending on its genetic makeup and where it begins. Clinicians often group these into a few clinical variants that reflect the underlying gene fusion and the tumor’s primary location. Not everyone will experience every type, and symptoms can range from a slow-growing lump to pain, swelling, or limits in movement, depending on the tumor site. Understanding the main variants can help you and your care team talk clearly about types of clear cell sarcoma and what to expect.
Classic soft-tissue
This variant usually arises in tendons or deep soft tissues of the arms or legs, often in younger adults. People may notice a firm, slowly enlarging lump that can become painful or limit movement over time. It commonly carries an EWSR1–ATF1 gene fusion.
Gastrointestinal type
This form starts in the stomach or small intestine and can cause belly pain, bleeding, or anemia rather than a visible lump. Some may have weight loss or fatigue from slow blood loss. It most often features an EWSR1–CREB1 gene fusion.
Uncommon fusion partners
A small subset shows other fusions within the same pathway, such as different partners in the EWSR1/CREB family. Symptoms are similar to the classic type and depend mostly on tumor size and location. These tumors are diagnosed with specialized genetic testing.
What genetics can tell you about symptoms
Some people with clear cell sarcoma have EWSR1‑ATF1 or EWSR1‑CREB1 fusions, which act like stuck “on” switches driving a slow‑growing mass, often deep in tendons or aponeuroses, and sometimes pain or swelling. These fusions can also increase spread to lymph nodes and lungs.
Causes and risk factors
Clear cell sarcoma is usually caused by a specific genetic change in the tumor cells, and it is not inherited. Most cases arise by chance, and no clear lifestyle or environmental triggers have been proven. It is more often found in teens and young adults, and family history is not known to raise risk. Having risk factors doesn’t mean you’ll definitely develop the condition. Risk also does not predict early symptoms of clear cell sarcoma.
Environmental and biological risk factors
Clear cell sarcoma is a rare soft-tissue cancer, and firm risk factors are limited. Researchers are still exploring how outside influences interact with our inner biology. As of now, environmental risk factors for clear cell sarcoma have not been clearly confirmed, and most people are diagnosed without a known exposure. The points below summarize what is known about biological patterns and suspected environmental links.
Clear cell sarcoma is more often diagnosed in teens and younger to middle-aged adults. That pattern points to biology rather than long-term external exposures, though it can occur at any age.
Rates appear similar in women and men across most groups. No consistent ancestry or racial pattern has been confirmed.
High-dose radiation to a body area can raise the long-term risk of several soft-tissue sarcomas. A specific link to clear cell sarcoma has not been clearly shown.
Studies on industrial chemicals and herbicides show mixed findings for soft-tissue sarcomas overall. No reliable association has been demonstrated for clear cell sarcoma.
Genetic risk factors
In clear cell sarcoma, the main genetic driver is a tumor-specific gene fusion involving the EWSR1 gene and a partner such as ATF1 or, less often, CREB1. When people ask about genetic risk factors for clear cell sarcoma, the key point is that these fusions arise in the cancer cells and are not typically inherited. Risk is not destiny—it varies widely between individuals. Doctors often confirm the diagnosis by testing the tumor for these fusions.
EWSR1-ATF1 fusion: A swap between chromosomes 12 and 22 creates a fusion gene that drives tumor growth. It is found in most clear cell sarcomas of soft tissue and helps confirm the diagnosis. The fusion turns on genes that would not normally be active together.
EWSR1-CREB1 fusion: A less common variant fuses EWSR1 with CREB1 and appears to act in a similar way. It occurs in a minority of cases. Identifying the partner gene can refine classification and research options.
Not inherited: These gene fusions happen after birth within the tumor cells (somatic changes). Family history is not a known risk factor for clear cell sarcoma. Routine germline testing usually does not find an inherited cause.
Secondary changes: Some tumors pick up additional genetic changes over time. These added changes may influence how aggressive the cancer is, but they do not represent inherited risk. The mix of changes can differ from tumor to tumor.
Distinct kidney tumor: A similarly named kidney tumor is a separate condition with different genetic drivers. It often involves BCOR-related changes or other fusions, not the EWSR1 fusions seen in soft tissue. Knowing the difference helps avoid confusion when reading about genetics.
Testing the tumor: Genetic tests on the tumor, such as FISH or sequencing, can detect EWSR1 fusions in a biopsy sample. Finding the fusion supports the diagnosis and helps distinguish it from look-alike tumors. These results usually do not point to a hereditary risk.
Lifestyle risk factors
Research on lifestyle risk factors for Clear cell sarcoma is limited, but certain habits can influence treatment tolerance, recovery, and overall outcomes. In practice, clinicians often apply evidence from soft-tissue sarcomas and broader oncology to guide supportive lifestyle choices. Understanding the lifestyle risk factors for Clear cell sarcoma can help you focus on behaviors that support care and reduce complications.
Smoking impairs wound healing and increases surgical and radiation complications. It is linked with worse cancer outcomes and higher infection risk.
Excess alcohol can strain the liver and interfere with medications used around surgery or systemic therapy. It can worsen dehydration and nutrition during treatment.
Low activity reduces cardiorespiratory fitness needed for surgery and rehab. It may increase fatigue and slow return to function after limb-sparing procedures.
Inadequate calories and protein increase risk of weight and muscle loss during treatment. This can impair healing, reduce therapy tolerance, and increase fatigue.
Risk prevention
Clear cell sarcoma doesn’t have a known way to prevent it, because it most often starts from a spontaneous gene change in the tumor, not something inherited or caused by lifestyle. Prevention focuses on noticing changes early and getting the right care quickly. Even if you can’t remove all risks, prevention can reduce their impact. Paying attention to early symptoms of clear cell sarcoma and seeking timely evaluation can make a meaningful difference.
Watch for a firm, painless lump in a foot, ankle, hand, or along a tendon that grows over weeks to months. Early symptoms of clear cell sarcoma can be subtle, so any new or changing lump deserves attention. Don’t wait for pain to appear.
See a clinician promptly for any mass that is enlarging, deeper than the skin, or about 5 cm (2 inches) or larger. Lumps that don’t settle after 4–6 weeks should be evaluated rather than observed indefinitely.
If a worrisome lump is found, request imaging and referral to a sarcoma center before any removal. Proper planning of biopsy and surgery lowers complications and helps achieve the best outcome in clear cell sarcoma.
After care for clear cell sarcoma, stick to the imaging and visit schedule your team recommends to catch recurrences early. Prevention works best when combined with regular check-ups.
Transmission
Clear cell sarcoma is not contagious. It does not spread from person to person through touch, sex, coughing, blood, or any kind of close contact.
There is no genetic transmission of clear cell sarcoma: it almost always develops from a DNA change (a gene fusion) that occurs only in the tumor cells during someone’s lifetime, not in the eggs or sperm. Because of this, clear cell sarcoma is not considered an inherited cancer, and parents do not pass it on to their children.
When to test your genes
Consider genetic testing if you’re diagnosed with clear cell sarcoma, if the tumor is suspected based on imaging/biopsy, or if treatment decisions are pending—results can confirm the EWSR1 gene fusion and guide therapy or trials. Testing is also reasonable for unexplained soft-tissue masses. Family testing isn’t usually needed.
Diagnosis
You might notice a firm, painless lump in an arm or leg that slowly gets bigger, or a nagging ache after activity. Doctors usually begin with a careful exam and imaging, then confirm the answer with a biopsy. Because clear cell sarcoma is rare, several steps are used together to be sure of the diagnosis and to check whether it has spread. Understanding how clear cell sarcoma is diagnosed can help you know what to expect.
Your provider asks about changes in a lump, pain, or limited movement and examines the area and nearby lymph nodes. This first look helps decide which tests come next.
MRI shows the exact size and edges of the mass and how it relates to muscles, tendons, and nerves. This detail helps distinguish soft tissue tumors and plan any procedure.
A chest CT checks whether cancer has spread to the lungs, a common travel route for soft tissue sarcomas. It also provides a baseline for future comparisons.
PET-CT highlights areas that are metabolically active, which can reveal hidden spread. It may also help guide biopsy to the most informative spot.
Stages of Clear cell sarcoma
Clear cell sarcoma is staged from I to IV to show how far it has spread and to guide treatment planning. Different tests may be suggested to help map the tumor’s size and whether it has reached lymph nodes or other organs. Staging considers tumor size, whether it has reached nearby nodes or distant organs, and how the cells look and behave under the microscope (grade). It’s based on imaging and biopsy findings rather than early symptoms of clear cell sarcoma.
Stage I localized
The cancer is only in the original area and looks low grade under the microscope. It is usually small (often under 5 cm/2 in) and has not reached lymph nodes or other organs.
Stage II higher grade
The tumor is still in one area but is higher grade or larger than very small tumors. Clear cell sarcoma remains confined, with no lymph node or distant spread.
Stage III large high-grade
The tumor is high grade and larger than about 5 cm (2 in), but still has not spread to lymph nodes or distant organs. It may press on nearby muscles, tendons, or nerves.
Stage IV spread present
The cancer has reached lymph nodes or distant organs, most often the lungs. Clear cell sarcoma in this stage may also involve other sites such as bone or the abdomen.
Outlook and prognosis
Looking ahead can feel daunting, but many people with clear cell sarcoma want to know how life and treatment may unfold over time. This cancer tends to grow slowly at first but has a real risk of spreading, especially to the lungs and nearby lymph nodes. Doctors call this the prognosis—a medical word for likely outcomes. Early diagnosis, complete surgical removal with clear margins, and close follow-up offer the best chance for long-term control.
The outlook is not the same for everyone, but several factors matter: tumor size, depth, location in the limb or trunk, involvement of lymph nodes, and whether it has already spread. Early symptoms of clear cell sarcoma can be subtle—often a painless lump—and catching it before it spreads improves survival. When found early and fully removed, many people remain disease-free for years, though late recurrences can happen, so long-term checkups are essential. If it spreads, treatment usually shifts to a combination of surgery when possible, targeted approaches through clinical trials, and sometimes radiation; traditional chemotherapy has limited benefit for this tumor type.
Understanding the prognosis can guide planning and day-to-day decisions. Report new or changing symptoms promptly, especially a new cough, shortness of breath, unexplained weight loss, or new lumps. Keep regular imaging and clinic visits, since small adjustments—like removing a small local recurrence or treating a single lung spot—can make a meaningful difference. Talk with your doctor about what your personal outlook might look like, including survival estimates and the role of clinical trials, because access to specialized sarcoma centers can improve options.
Long-term effects
Clear cell sarcoma is an uncommon soft tissue cancer that can behave slowly at first but act aggressively over time. Long-term effects vary widely, depending on tumor size, location, spread, and treatment. Knowing the early symptoms of clear cell sarcoma can lead to earlier treatment, but long-term outlook still hinges on whether it has spread and if it can be fully removed. The long view can feel uncertain, but support and regular follow-up imaging help catch recurrences when they are more treatable.
Clear cell sarcoma can return in the same area months to years after surgery. Risk is higher when the original tumor was large or margins were close. Ongoing imaging is often needed for many years.
This cancer has a higher tendency than many soft tissue sarcomas to spread to nearby lymph nodes. Nodes may be removed or treated if involved. Swelling of the limb can follow.
The lungs are the most common distant site for clear cell sarcoma. Late cough, chest pain, or shortness of breath can appear if lesions grow. Lung spread strongly influences survival over the long term.
Less often, cancer cells reach the bones, liver, or other organs. This can lead to bone pain, fractures, or abdominal discomfort. These patterns may emerge years after initial treatment.
How is it to live with Clear cell sarcoma?
Living with clear cell sarcoma often means pacing your days around treatment plans, scans, and follow-up visits, while also guarding energy for work, family, and the parts of life that feel normal. Some people manage pain, stiffness, or limited function in an arm or leg after surgery or radiation, and may use physical therapy or mobility aids to stay active and independent. The emotional load—uncertainty, watchful waiting, and worry about recurrence—can spill over to partners, children, and friends, who often become key supports but may need their own space and guidance to cope. Many find that planning ahead, leaning on a care team and peer support, and celebrating small milestones helps keep life grounded and hopeful.
Treatment and drugs
Clear cell sarcoma is treated with a mix of surgery, targeted approaches when available, and supportive care to manage symptoms and function. When possible, surgeons aim to remove the entire tumor with a rim of healthy tissue; if margins are close or the tumor can’t be fully removed, radiation therapy may be used to lower the chance of it coming back. Chemotherapy has limited benefit for clear cell sarcoma, but it may be considered in selected cases or in a clinical trial, and newer options like targeted drugs or immunotherapy are sometimes offered through trials based on the tumor’s features—when treatment is tailored to your genes, it’s often called personalized medicine. For disease that has spread, treatment often focuses on controlling growth with systemic therapies, easing pain and swelling, and maintaining mobility with physical therapy. Ask your doctor about the best starting point for you, including whether a sarcoma specialty center or a clinical trial could expand your options.
Non-drug treatment
Treatment for clear cell sarcoma often centers on surgery and radiation, with several non-drug supports that help you heal, move, and return to daily life. Non-drug treatments often lay the foundation for recovery before, during, and after cancer treatment. Recognizing early symptoms of clear cell sarcoma—like a painless, growing lump—can prompt earlier evaluation and a smoother rehab plan. Plans are individualized based on tumor location, stage, and your goals.
Wide removal of the tumor with a margin of healthy tissue is the main local treatment. When possible, limb-sparing techniques and reconstruction help preserve function.
Radiation may be used before or after surgery to reduce the risk of the cancer returning in the same area. Focused radiation can also treat small spots of disease in the lungs or other sites.
Physical therapy helps restore strength, flexibility, and balance after surgery or radiation. Therapists tailor exercises to the tumor’s location so daily movement feels safer and easier.
Training focuses on everyday tasks like dressing, cooking, and work duties after limb or hand procedures. Adaptive tools or task modifications can reduce strain and protect healing tissues.
Your genes may have an impact on how drugs work for you
Some drugs for clear cell sarcoma work better—or cause more side effects—depending on tumor genetics, like specific gene fusions that can make targeted therapies more or less effective. Your inherited genes also affect how your body processes medicines, influencing dose and tolerability.
Pharmacological treatments
Medicines are mainly used for clear cell sarcoma when surgery and radiation are not possible or the cancer has spread. Even if early symptoms of clear cell sarcoma are easy to miss, drug therapy is usually considered for advanced or unresectable disease. Not everyone responds to the same medication in the same way. When helpful, these drugs aim to slow growth, ease symptoms, and lengthen time before the cancer worsens.
Often the first chemotherapy tried for advanced soft tissue sarcomas, including clear cell sarcoma. It is given by IV in cycles and requires heart and blood count monitoring.
Sometimes used with doxorubicin to improve response in advanced disease. It needs careful kidney and bladder protection and close monitoring for low blood counts.
A combination used when anthracycline therapy like doxorubicin is not suitable or has stopped working. It may slow tumor growth in some people with clear cell sarcoma.
Alkylating drugs that can be options when other treatments are limited. Benefits in clear cell sarcoma are variable, so doctors individualize use based on prior therapies and tolerance.
Genetic influences
Most cases start with a specific DNA change inside the tumor cells rather than something you were born with. In clear cell sarcoma, this change is usually a gene fusion—two genes abnormally joined together—most often involving EWSR1 and ATF1, and less often CREB1. This fusion drives cell growth, but it’s a somatic change, meaning it isn’t typically inherited and usually doesn’t raise risk for relatives. When doctors analyze the tumor, DNA testing can sometimes identify these changes. Finding the fusion helps confirm the diagnosis of clear cell sarcoma and may inform treatment plans or eligibility for research studies. Because this cancer is generally not passed down, routine testing of family members isn’t needed; a genetics visit may be considered only if there’s a broader pattern of cancers in the family. If you’re wondering about next steps, ask your care team about genetic testing for clear cell sarcoma focused on the tumor, not your inherited DNA.
Is Clear cell sarcoma genetic?
Genetics is central in clear cell sarcoma. Most tumors carry a specific gene fusion—often EWSR1-ATF1, sometimes EWSR1-CREB1—which drives growth and helps confirm diagnosis. These changes are usually not inherited; family risk is generally low.
Pharmacogenetics—how genetics influence drug effects
In Clear cell sarcoma, treatment planning increasingly leans on the tumor’s genetics. Most tumors carry a specific gene fusion—a piece of the EWSR1 gene joined to ATF1 (or sometimes CREB1)—and finding this change helps confirm the diagnosis and match people to clinical trials of targeted medicines. There isn’t yet an approved drug that directly blocks this fusion, and results with immunotherapy have been mixed because Clear cell sarcoma usually has few DNA changes. For standard drugs such as doxorubicin, ifosfamide, or pazopanib, routine pharmacogenetic testing isn’t part of care; doses are set by body size, liver and kidney tests, and how treatment is tolerated. Alongside medical history and organ function, genetic testing can sometimes identify how your body responds to certain medicines. Genetic testing for Clear cell sarcoma typically focuses on the tumor to detect the fusion and to look for rare changes that might open a targeted option, while separate pharmacogenetic tests may be considered if there’s a history of unusual side effects with pain or anti-nausea medications.
Interactions with other conditions
Clear cell sarcoma can be mistaken for melanoma because the tumor cells share some of the same pigment-related features under the microscope; getting the diagnosis right matters because treatments differ. Another important aspect is how it may link with other diseases. If someone also lives with diabetes, heart disease, or lung conditions, recovery from surgery and tolerance of treatments like radiation or systemic therapy may be harder, and your team will plan around that. People with autoimmune conditions or those taking long-term immune‑suppressing medicines may have different risks and benefits if immunotherapy is considered, so specialists often coordinate closely. Lymph nodes and lungs are common sites where clear cell sarcoma can spread, so infections, blood clots, or breathing problems from other illnesses can complicate monitoring and may change how often scans are done. Because early symptoms of clear cell sarcoma can be subtle—like a small, painless lump near a tendon—let your care team know about any new masses even if you already have another diagnosis, and talk with your doctor about how your conditions may influence each other.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns that puzzled them: a firm lump in a limb of an otherwise healthy young adult that slowly grew, stayed oddly quiet for a time, then spread to lymph nodes months or years later. Long before scans and lab tests, surgeons recorded these stubborn tumors near tendons or fascia in the arms and legs, often in people in their teens to thirties who were active and well.
First described in the medical literature as a distinct soft tissue cancer in the mid-20th century, clear cell sarcoma was initially grouped with other melanocytic tumors because the cells looked pigmented under the microscope and stained like melanoma. Early reports called it “malignant melanoma of soft parts,” though the term has largely been replaced as its unique biology became clear. As case series accumulated, doctors noticed a signature pattern: tumors arising deep in the extremities, a slow initial course, and a tendency to spread to nearby lymph nodes more than many other sarcomas do.
With each decade, pathology advanced. Immunostaining sharpened the picture, but it was the rise of molecular genetics in the late 20th century that changed the story. Researchers identified a recurring chromosomal swap—most often between chromosomes 12 and 22—that fuses parts of two genes into one. This EWSR1–ATF1 fusion, and less commonly EWSR1–CREB1, became a defining marker, helping separate clear cell sarcoma from melanoma and other soft tissue tumors that can look similar. For people with unclear biopsy results, this genetic “signature” offered firmer answers and more confident diagnoses.
Once considered rare, now recognized as an uncommon but distinct sarcoma, clear cell sarcoma moved from being a puzzling look‑alike to a clearly profiled entity in cancer classifications. This shift influenced care: surgeons planned wider resections when feasible, pathologists checked lymph nodes more carefully, and multidisciplinary teams followed people longer, knowing late recurrences can occur.
In recent decades, awareness has grown about differences within clear cell sarcoma. Some tumors arise in the foot or ankle, others higher up in the leg or arm; a smaller number start in the trunk or near the gastrointestinal tract. The pace can vary—many grow slowly at first, while a subset progresses more quickly. These observed patterns, combined with genetic testing, shaped today’s approach to staging and follow‑up.
Current studies build on a long tradition of observation, using modern tools to explore targeted treatments that address the fusion proteins driving the cancer. While no single therapy has transformed outcomes yet, clinical trials continue, and shared international registries are improving knowledge in this rare disease. Knowing the condition’s history helps explain why accurate diagnosis—grounded in both careful pathology and molecular testing—remains the foundation of care for people living with clear cell sarcoma.